Choose your Language


Some areas of this website are accessible to registered members only.

If you have no account yet, please click on "Register".
If you have forgotten your password, please click on "Forgot login?".



The European Patients' Academy (EUPATI) is a pan-European Innovative Medicines Initiative project of 33 organizations, led by the European Patients' Forum, with partners from patient organizations (the European Genetic Alliance, the European AIDS Treatment Group, and EURORDIS), universities and not-for-profit organisations, along with a number of European pharmaceutical companies.

We aim to help patients be more educated and involved in the research and development process of new medicines by offering reliable, objective, comprehensive lay-friendly information and training on the research and development process of medicines. We will increase the capacity of patients to be effective advocates with meaningful involvement in areas like drug discovery and non-clinical testing, planning and conduct of clinical trials, regulatory affairs, assessment of safety of medicines, benefit-risk assessment, as well as principles of health technology assessment.

We launched the in-depth EUPATI Patient Expert Training Course in October 2014 and we are launching a web-based educational toolbox, hosting educational material in English, Italian, Spanish, Polish, German, French and Russian from January 2016, aiming to reach 12,000 patient advocates across Europe.



Medicines development is a highly regulated, costly, long and complex process that is largely a mystery to the general public. The benefits and risks of medical treatments are difficult to understand for the person on the street, even though we spend an average of 9.5% of our national GDPs on healthcare (EC Eurostat, September 2012). Today, in a time of growing demand on both quality and sustainability of healthcare, it is important for us all to understand healthcare better. 

Read more ...

We focus on education and training to improve the availability of patient-friendly information for the public as well as for more advanced patient advocates and patient experts to give you the capacity and capability to understand and contribute to medicines research & development.

Read more ...

The European Patients’ Academy will develop educational modules in the following areas:

Our collaborative team includes European leaders in patient advocacy, universities, not-for-profit organisations and pharmaceutical companies, bringing in key expertise in patient advocacy as well as in the processes of medicines research and development.

Our team is led by the European Patients’ Forum and unites us all.

Read more ...

The European Patients’ Academy will specifically target people speaking the seven most frequently spoken languages (English, French, German, Spanish, Polish, Italian and Russian), directly serving 12 countries (Austria, (Francophone) Belgium, France, Germany, Ireland, Italy, Luxemburg, Malta, Poland, Spain, (the German-speaking part of) Switzerland, UK, and CEE countries that speak Russian). We will focus on three groups:

Read more ...

The European Patients' Academy was launched in February 2012 to run for five years. Our project is organized into seven working groups that will ensure the professional and efficient delivery of services. The seven groups include:

Read more ...

The European Patients’ Academy includes a multidisciplinary Project Advisory Board, a Regulatory Advisory Panel and an Ethics Panel comprising renowned experts who provide us with independent and objective advice to maintain strong governance.

Read more ...

Objectivity, transparency and independence are essential to achieving our goals with patients and the general public.

Our commitment to these core principles is reflected in our work practices:

Read more ...

The "European Patients' Academy on Therapeutic Innovation" project is receiving support from the Innovative Medicines Initiative Joint Undertaking under grant agreement n° 115334, resources of which are composed of financial contribution from the European Union‘s Seventh Framework Programme (FP7/2007-2013) and EFPIA companies.

About IMI

The Innovative Medicines Initiative (IMI) is Europe's largest public-private initiative aiming to speed up the development of better and safer medicines for patients. IMI is a joint undertaking between the European Union and the pharmaceutical industry association EFPIA. IMI supports collaborative research projects and builds networks of industrial and academic experts in order to boost pharmaceutical innovation in Europe.

eu-logo-60px  imi-logo-60px  efpia-logo-60px

Do you want to learn more about the research and development of medicines? The European Patients’ Academy is inviting people to join the Network. Membership to the Network is free and open to anyone interested in finding information on medicines research & development. The Network offers members the following benefits:

  • invitations to European Patients’ Academy activities and events
  • networking opportunities
  • invitations to participate in our surveys and focus groups
  • opportunities to collaborate with other members

You can join the European Patients’ Academy Network today by registering at